Pharmacotherapy for the prevention of post-ERCP pancreatitis
- PMID: 17266688
- DOI: 10.1111/j.1572-0241.2006.00950.x
Pharmacotherapy for the prevention of post-ERCP pancreatitis
Abstract
Post-ERCP pancreatitis (PEP) is a potential complication of ERCP. Pharmacotherapy for prevention of PEP aims at reducing basal sphincter pressure and contractility or a decrease in pancreatic secretion to reduce intraductal pressure. Timing and route of administration of drugs are critical to ensure maximum benefits from medications. Pancreatic stenting offers an alternative to decompress the pancreas and is effective in reducing PEP in high-risk patients.
Comment on
-
Effect of octreotide administration in the prophylaxis of post-ERCP pancreatitis and hyperamylasemia: A multicenter, placebo-controlled, randomized clinical trial.Am J Gastroenterol. 2007 Jan;102(1):46-51. doi: 10.1111/j.1572-0241.2006.00959.x. Am J Gastroenterol. 2007. PMID: 17266687 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
